A carregar...
NDUFA4L2 promotes trastuzumab resistance in HER2-positive breast cancer
BACKGROUND: Trastuzumab (Herceptin) is the key systemic therapy for HER2-positive breast cancer. However, the initial response rate is limited to approximately 50% in patients. Moreover, most patients, especially at an advanced stage, eventually develop acquired resistance. Understanding the mechani...
Na minha lista:
| Publicado no: | Ther Adv Med Oncol |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
SAGE Publications
2021
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8256255/ https://ncbi.nlm.nih.gov/pubmed/34276814 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/17588359211027836 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|